Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

Scroll to Top